Houte Hans Van Sells 3,546 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 3,546 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $24.28, for a total value of $86,096.88. Following the completion of the transaction, the chief financial officer now owns 33,724 shares of the company’s stock, valued at $818,818.72. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Wednesday, October 30th, Houte Hans Van sold 2,368 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.30, for a total value of $57,542.40.
• On Monday, August 26th, Houte Hans Van sold 20,000 shares of Nurix Therapeutics stock. The stock was sold at an average price of $25.22, for a total value of $504,400.00.

Nurix Therapeutics Trading Down 0.4 %

Shares of NRIX traded down $0.11 during midday trading on Friday, reaching $24.47. 618,495 shares of the company were exchanged, compared to its average volume of 883,651. Nurix Therapeutics, Inc. has a 1-year low of $4.96 and a 1-year high of $27.60. The stock has a 50-day moving average price of $24.21 and a 200-day moving average price of $20.20.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Friday, October 11th. The company reported ($0.67) EPS for the quarter, hitting the consensus estimate of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The firm had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. Equities analysts forecast that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Amalgamated Bank boosted its position in Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after buying an additional 511 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Nurix Therapeutics by 31.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock worth $54,000 after acquiring an additional 559 shares in the last quarter. International Assets Investment Management LLC boosted its holdings in Nurix Therapeutics by 1,098.4% in the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after purchasing an additional 4,119 shares during the last quarter. GAMMA Investing LLC grew its stake in Nurix Therapeutics by 299.8% during the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after purchasing an additional 3,424 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new stake in Nurix Therapeutics during the 1st quarter worth approximately $123,000.

Wall Street Analysts Forecast Growth

Several research firms have commented on NRIX. Oppenheimer lifted their price target on Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday, September 4th. Jefferies Financial Group initiated coverage on shares of Nurix Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $41.00 price target for the company. Truist Financial started coverage on shares of Nurix Therapeutics in a research note on Wednesday, July 31st. They set a “buy” rating and a $36.00 price target on the stock. HC Wainwright boosted their price objective on shares of Nurix Therapeutics from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, Barclays increased their target price on Nurix Therapeutics from $20.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, July 15th. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.40.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.